10 recruiting, 5 unknown, 4 not yet recruiting, 3 active not recruiting. 12 Phase 1, 10 Phase 2, 3 Early Phase 1, 2 Phase 3, 1 Not applicable.
Follow Relapse Multiple Myeloma: new trials by email Literature Review of Relapse Multiple Myeloma trials Research Report on Relapse Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) Talquetamab, Belantamab mafodotin, Pomalidomide - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Montefiore Medical Center | 50 | 2026-09-01 | 2026-07-22 |
| FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma FT836 CAR T cells (1 x 10^8 cells per dose), FT836 CAR T cells (3 x 108 cells per dose), FT836 CAR T cells (up to 9 x 108 cells per dose) - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2026-08-05 | 2026-11-04 |
| Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma Belantamab mafodotin, Bortezomib, Dexamethasone - Relapse Multiple Myeloma | Not yet recruiting | PETHEMA Foundation | 100 | 2026-06-01 | 2026-06-24 | |
| Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Natalie Callander | 62 | 2026-05-21 | 2026-08-31 |
| DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM DC/MM Fusion Vaccine, GM-CSF - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2026-01-30 | 2026-05-08 |
| Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma Talquetamab, Ciltacabtagene Autoleucel - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Medical College of Wisconsin | 31 | 2025-12-02 | 2026-01-05 |
| Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma Dual CD19/BCMA CAR-T - Relapse Multiple Myeloma | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 25 | 2025-11-01 | 2026-01-22 |
| Melflufen for Elderly Patients With Relapsed Myeloma Melflufen, Dexamethasone - Relapse Multiple Myeloma | Phase 2 | Withdrawn | Fondazione EMN Italy Onlus | 2025-03-26 | 2025-04-01 | |
| A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma Elranatamab, GM-CSF, DC/MM Fusion Vaccine - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2025-01-31 | 2026-05-07 |
| Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone Dexamethasone - Multiple Myeloma, Relapse Multiple Myeloma | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 318 | 2024-12-12 | 2024-12-18 |
| MMRC Horizon One: RRMM (MMRC-099) Teclistamab Monotherapy, Teclistamab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Multiple Myeloma Research Consortium | 300 | 2024-11-17 | 2026-06-05 |
| Elranatamab in R/R Multiple Myeloma Elranatamab - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 32 | 2024-03-08 | 2026-08-31 |
| Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma Belantamab mafodotin, Carfilzomib, Pomalidomide - Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Recruiting | University of Chicago | 83 | 2023-05-30 | 2026-09-23 |
| A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases Relapse Multiple Myeloma, Refractory Multiple Myeloma | Completed | Pfizer | 121 | 2023-05-26 | 2026-07-09 | |
| Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma Belantamab mafodotin - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Terminated | Medical College of Wisconsin | 1 | 2022-07-19 | 2025-01-28 |
| A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma BCMA Targeted CAR T-cells - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Early Phase 1 | Unknown | Zhejiang University | 100 | 2022-06-20 | 2022-06-24 |
| A Study of MCARH109 and MCARH125 in People With Multiple Myeloma MCARH125, MCARH109 - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 15 | 2022-06-20 | 2026-07-06 |
| Descartes-25 in Relapsed/Refractory Multiple Myeloma Descartes-25 - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Terminated | Cartesian Therapeutics | 9 | 2021-11-25 | 2024-11-12 |
| A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab Daratumumab SC, Clarithromycin, Pomalidomide - Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 11 | 2021-10-28 | 2026-05-20 |
| Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma CAR-BCMA - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Sheba Medical Center | 75 | 2021-09-19 | 2024-01-31 |
Showing 20 of 29. Sign in to see all of them.
Multiple Myeloma (25) · Neoplasm, Residual (1) · Neoplasms, Plasma Cell (1) · Recurrence (1)
Blood Protein Disorders (25) · Cardiovascular Diseases (25) · Hematologic Diseases (25) · Hemic and Lymphatic Diseases (25) · Hemorrhagic Disorders (25) · Hemostatic Disorders (25) · Immune System Diseases (25) · Immunoproliferative Disorders (25) · Lymphoproliferative Disorders (25) · Neoplasms (25) · Neoplasms by Histologic Type (25) · Paraproteinemias (25) · Vascular Diseases (25) · Neoplasms, Plasma Cell (24) · Pathologic Processes (2)
Dexamethasone (7) · pomalidomide (5) · belantamab mafodotin (4) · carfilzomib (4) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · talquetamab (2) · BID protein, human (1) · Bortezomib (1) · Calcium Dobesilate (1) · Clarithromycin (1) · daratumumab (1) · isatuximab (1) · melflufen (1) · selinexor (1)
Medical College of Wisconsin (4) · Zhejiang University (3) · David Avigan (2) · Ajai Chari (1) · Assistance Publique - Hôpitaux de Paris (1) · Black Sea Hematology Association (1) · Cartesian Therapeutics (1) · Fondazione EMN Italy Onlus (1) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Montefiore Medical Center (1) · Multiple Myeloma Research Consortium (1) · Natalie Callander (1) · National University Hospital, Singapore (1) · Oncopeptides AB (1)
United States (13) · China (5) · Turkey (Türkiye) (3) · Italy (2) · Czechia (1) · France (1) · Hong Kong (1) · Israel (1) · Japan (1) · Singapore (1) · South Korea (1) · Taiwan (1)
Binod Dhakal, MD (2) · Ajai Chari, MD (1) · Benjamin Derman, MD (1) · David Avigan, MD (1) · David R Levitz, MD (1) · Hearn J Cho, MD, PhD (1) · Jacalyn Rosenblatt, MD (1) · Javier de la Rubia (1) · Li Yu (1) · Mateo Mejia Saldarriaga, MD (1) · Meera Mohan, MD, MS (1) · Mehmet Turgut, Prof (1) · Natalie Callander, MD (1) · Noopur Raje, MD (1)